HER2 Assay Kit Market: Size, Share, and Growth Outlook to 2035

The HER2 Assay Kit Market is experiencing significant growth, driven by the rising incidence of HER2-positive breast cancer, advancements in diagnostic technologies, and the growing demand for personalized medicine. According to detailed industry evaluation, the market was valued at USD 2,452.7 million in 2025 and is projected to reach USD 4,500 million by 2035, exhibiting a CAGR of 6.3% during the forecast period 2026-2035. Single test kits, multiplex test kits, instruments, and reagents remain among the most sought-after products globally due to their critical role in determining HER2 expression levels, guiding therapeutic decisions, and improving patient outcomes in breast cancer treatment. Furthermore, the increasing prevalence of breast cancer, growing awareness of personalized medicine, and rising investment in clinical research are broadening the adoption base across hospitals, diagnostic laboratories, research institutions, and pharmaceutical companies.

By application, breast cancer diagnosis holds the majority share, valued at USD 980 million in 2024 and projected to rise to USD 1,800 million by 2035, driven by the increasing prevalence of breast cancer globally and advancements in diagnostic technologies. By technology, immunohistochemistry has established itself as a prominent method due to its ability to provide visual evidence of HER2 protein expression, while fluorescence in situ hybridization is widely utilized for confirming HER2 gene amplification. By product type, single test kits currently emerge as the most prominent segment, reflecting strong performance due to ease of use and high accuracy. Recent developments include Roche launching the VENTANA HER2 Dual ISH v9 kit, a next-generation HER2 assay intended to improve concordance and workflow automation, Thermo Fisher Scientific announcing a strategic partnership with Abbott Laboratories to co-develop integrated HER2 testing workflows, and Abbott Laboratories securing a major contract to supply HER2 assay kits to a national network of cancer centers.

North America is currently dominating the market, with a valuation of USD 970 million in 2024, expected to grow to USD 1,800 million by 2035, showcasing robust demand driven by advanced healthcare infrastructure and high spending on research and development. Europe is witnessing steady expansion, while the Asia-Pacific region is on a growth trajectory, supported by a rising prevalence of breast cancer and increasing investments in healthcare technologies. The competitive landscape features key players including Abbott Laboratories, Thermo Fisher Scientific, F. Hoffmann-La Roche, Cell Signaling Technology, Agilent Technologies, Bio-Rad Laboratories, QIAGEN, Genentech, Roche, Invitrogen, Bristol-Myers Squibb, Myriad Genetics, PerkinElmer, Merck & Co., and Dako.

FAQs

What is the current market size of the HER2 assay kit market?
The market was valued at USD 2,452.7 million in 2025 and is projected to reach USD 4,500 million by 2035, exhibiting a CAGR of 6.3%.

Which segment dominates the HER2 assay kit market?
Breast cancer diagnosis holds the largest market share by application, while single test kits lead by product type. Immunohistochemistry is the dominant technology.

Who are the key players in the HER2 assay kit market?
Key players include Abbott Laboratories, Thermo Fisher Scientific, F. Hoffmann-La Roche, Cell Signaling Technology, Agilent Technologies, Bio-Rad Laboratories, QIAGEN, Genentech, Roche, Invitrogen, Bristol-Myers Squibb, Myriad Genetics, PerkinElmer, Merck & Co., and Dako.

#HER2AssayKitMarket #BreastCancerDiagnostics #PersonalizedMedicine #OncologyTesting #PrecisionMedicine